Search research articles
Contact Us
Filters
Showing results (91-100 of 105) with videos related to
Page
of 11
Sort By:
European Urology
|
October 27, 2023
Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study
Renu S Eapen, James P Buteau, Price Jackson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 5, 2023
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database
Louise Emmett, Nathan Papa, William Counter, et al.
The Journal of Urology
|
May 17, 2024
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer
Louise Emmett, Nathan Papa, Thomas A Hope, et al.
European Urology Oncology
|
January 21, 2026
Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial
Thomas Zilli, Shankar Siva, Sigmund Brabrand, et al.
The Lancet. Oncology
|
May 17, 2026
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
Shankar Siva, David Pryor, Jarad Martin, et al.
The Lancet. Oncology
|
May 8, 2025
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial
Piet Ost, Shankar Siva, Sigmund Brabrand, et al.
European Urology Focus
|
January 2, 2021
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases
Thomas Zilli, Piet Dirix, Reino Heikkilä, et al.
European Urology Oncology
|
October 11, 2023
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial
Piet Ost, Shankar Siva, Sigmund Brabrand, et al.
European Urology
|
September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study
Louise Emmett, James Buteau, Nathan Papa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2021
Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival
Ken Chow, Justin Bedő, Andrew Ryan, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 105) with videos related to
Sort By:
Page
of 11
European Urology
|
October 27, 2023
Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study
Renu S Eapen, James P Buteau, Price Jackson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 5, 2023
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database
Louise Emmett, Nathan Papa, William Counter, et al.
The Journal of Urology
|
May 17, 2024
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer
Louise Emmett, Nathan Papa, Thomas A Hope, et al.
European Urology Oncology
|
January 21, 2026
Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized Trial
Thomas Zilli, Shankar Siva, Sigmund Brabrand, et al.
The Lancet. Oncology
|
May 17, 2026
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
Shankar Siva, David Pryor, Jarad Martin, et al.
The Lancet. Oncology
|
May 8, 2025
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial
Piet Ost, Shankar Siva, Sigmund Brabrand, et al.
European Urology Focus
|
January 2, 2021
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases
Thomas Zilli, Piet Dirix, Reino Heikkilä, et al.
European Urology Oncology
|
October 11, 2023
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial
Piet Ost, Shankar Siva, Sigmund Brabrand, et al.
European Urology
|
September 1, 2021
The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study
Louise Emmett, James Buteau, Nathan Papa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2021
Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival
Ken Chow, Justin Bedő, Andrew Ryan, et al.
Page
of 11